Silver MPN Center

We are saddened to share the loss of Richard T. Silver, MD, namesake of the @WeillCornell Silver MPN Center. His numerous contributions to the field profoundly impacted the lives of his patients and colleagues. Learn more about his life and legacy: bit.ly/4sM7B5F

With deep sadness, we mourn the loss of Dr. Richard Silver—a pioneer, mentor, and remarkable human. He transformed cancer care and touched countless lives through his devotion to patients, compassion, and belief in others. His legacy lives on. May his memory be a blessing.

.@WeillCornell #research compared different prognostic models for #PolycythemiaVera that are commonly used to guide initial treatment. Learn more from Silver MPN Center team member Katie Erdos: bit.ly/48ABTQT

Learn more about @WeillCornell #MyeloproliferativeNeoplasm (#MPN) #research on JAK2V617F variant allele frequency (VAF) in #PolycythemiaVera via @CTFrancoMD bit.ly/4ougw9A #ASH25

At #ASH25, @CTFrancoMD shared results of technology developed @WeillCornell to determine clonal fitness of #MPN cells using patient samples: bit.ly/48fdUaV

From #ASH25: Dr. Joseph Scandura was involved with #research evaluating a combination treatment for #MyeloproliferativeNeoplasm patients with #Myelofibrosis bit.ly/4rys9iN

Research program assistant Katie Erdos shared #research at #ASH25 looking at outcomes of primary #Myelofibrosis patients treated with interferon alfa: bit.ly/4iy2Ysz #MyeloproliferativeNeoplasms

Dr. Joseph Scandura was part of a phase 3 #ClinicalTrial presented at #ASH25 on rusfertide for #PolycythemiaVera. Learn more about the longer-term follow-up results: bit.ly/48hysj8

Tomorrow morning at #ASH25: Dr. Joseph Scandura will be speaking during an interactive industry forum session on unmet needs and emerging therapies for #PolycythemiaVera

We are proud to share a new documentary honoring Richard T. Silver, MD — a trailblazer in hematology and co-founder of the #MPNCongress. His extraordinary career & legacy continue to inspire. Watch here 👉bit.ly/RTSDocumentary #MPN #CML #DrRichardTSilver @WCMSilverMPNCtr

Dr. Joseph Scandura describes how the investigational drug rusfertide works for #PolycythemiaVera. He led the #ClinicalTrial @WeillCornell looking at the effectiveness of this treatment, with results presented during the plenary session today at #ASCO25: bit.ly/3HgP3Zn

Clinical research @WeillCornell @nyphospital is dedicated to innovating, inspiring and transforming lives. On #ClinicalTrialsDay, some of our team members who support clinical research are sharing how we are Powered By Purpose. #CTD2025 @ACRPDC

This year’s World Cancer Day theme is "United by Unique." Our collaborative approach to cancer care ensures patients receive top evaluations and therapies, including advancements in precision medicine and immune-based treatments. We make the fight against cancer personal.

#Research led by @WeillCornell Silver MPN Center team members, including research program assistant Neville Lee, Jr., evaluated the newer interferon ROPEG to the more commonly used PEG in #PolycythemiaVera patients: bit.ly/3CYU5aK #ASH24

From #ASH24: @WeillCornell team members evaluated the #MPN Personalized Risk Calculator (MPN-PRC) in determining overall survival, progression to #Myelofibrosis, and leukemic transformation in patients with #PolycythemiaVera bit.ly/4ihS5ui

Additional artificial intelligence (#AI) #research conducted by @WeillCornell & @StonyBrookMed team members and shared at #ASH24 found that certain cell traits are shared amongst #MyeloproliferativeNeoplasm patients with worse outcomes: bit.ly/3CZQKZ3

Dr. @GhaithAbuZeinah breaks down #research findings that determined DNMT3A mutations do not affect outcomes in patients with #PolycythemiaVera treated with interferon-alpha (IFN): bit.ly/3VpHN1n #ASH24

Researchers from @WeillCornell and @StonyBrookMed utilized a form of artificial intelligence (#AI) to detect mutations in bone marrow biopsy images from patients with #MyleoproliferativeNeoplasms: bit.ly/3ODKdFS #ASH24